Académique Documents
Professionnel Documents
Culture Documents
CME EDUCATIONAL OBJECTIVE: Readers will be aware of major advances in the assessment and treatment of
CREDIT chronic obstructive pulmonary disease
C L E V E L A N D C L I N I C J O U R N A L O F M E D I C I N E V O L U M E 8 1 N U M B E R 6 J U N E 2 0 1 4 373
Downloaded from www.ccjm.org on August 17, 2014. For personal use only. All other uses require permission.
COPD UPDATE
Downloaded from www.ccjm.org on August 17, 2014. For personal use only. All other uses require permission.
HATIPOGLU AND ABOUSSOUAN
Thus, a patient with an FEV1 of 60% (mod- correspond to a CAT score of 10 or higher,
erate airflow limitation) who has had one ex- classifying patients with health status impair-
acerbation during the past year and a CAT ment as asymptomatic (mean weighted kappa
score of 8 would be in group A. In contrast, a 0.626). The two tools agreed much better
patient who has an FEV1 of 40% (severe air- when the cutoff was set at an mMRC grade of
flow limitation), no history of exacerbations, 1 or higher (mean weighted kappa 0.792).16
and a CAT score of 20 would be in group D. Although assessment schemes continue to
Updated GOLD guidelines suggest utiliz- evolve as data accumulate, we believe the new
ing a stepwise approach to treatment, akin to system is a welcome initiative that reflects the
asthma management guidelines, based on pa- changing notions of COPD.
tient grouping.5
Comorbidities matter
How accurate is the new GOLD system? Another shift is the recognition that certain
Although practical and suited for use in pri- comorbidities increase the risk of death. In
mary care, the new GOLD system is arbitrary 1,664 patients with COPD who were followed
and has not been thoroughly studied, and may for 51 months, 12 distinct comorbidities were
therefore need refinement. associated with a higher risk of death after
Lange et al14 compared the new GOLD multivariate analysis.17
system with the previous one in 6,628 patients The COTE index (COPD-Specific Co-
with COPD. As anticipated, the new system morbidity Test) is based on these findings. It
was better at predicting exacerbations, as it in- awards points as follows:
corporates a history of exacerbations in strati- 6 points for cancer of the lung, esophagus,
fication. The presence of symptoms (as deter- pancreas, or breast, or for anxiety
mined by an mMRC grade 2) was a marker 2 points for all other cancers, liver cir-
of mortality risk that distinguished group A rhosis, atrial fibrillation or flutter, diabetes
from group B, and group C from group D. Sur- with neuropathy, or pulmonary fibrosis
prisingly, the rate of death was higher in group 1 point for congestive heart failure, gastric or
B (more symptoms, low risk) than in group C duodenal ulcer, or coronary artery disease. The best
(fewer symptoms, high risk). A COTE index score of 4 or higher was as-
Notably, most patients in group C quali- sociated with a risk of death 2.2 times higher predictor of
fied for this group because of the severity of in each quartile of the BODE index. exacerbations
airflow obstruction, not because of a history We strongly recommend being aware of
comorbidities in COPD patients, particularly is a history of
of exacerbations. Therefore, patients whose
symptoms are out of proportion to the severity when symptoms are out of proportion to the exacerbations
of obstruction may be at higher risk of death, severity of obstruction.
possibly because of comorbidities such as car-
diovascular disease.15 Patients who qualified SHOULD I USE ANTIBIOTICS TO TREAT
for groups C and D by having both a history ALL COPD EXACERBATIONS?
of frequent exacerbations ( 2 per year) and Infections are thought to cause more than
symptoms rather than either one alone had a 80% of acute exacerbations of COPD.
higher risk of death in 3 years. Anthonisen et al,18 in a landmark trial,
Similarly, the symptom-assessment tool found broad-spectrum antibiotics to be most
that is usedie, the mMRC grade or the CAT helpful if the patient had at least two of the
scorealso makes a difference. three cardinal symptoms of COPD exacerba-
The Health-Related Quality of Life in tion (ie, shortness of breath, increase in spu-
COPD in Europe Study16 retrospectively tum volume, and sputum purulence). Antibi-
analyzed data from 1,817 patients to deter- otics decreased the rate of treatment failure
mine whether the cutoff points for symptoms and led to a more rapid clinical resolution of
as assessed by mMRC grade and CAT score exacerbation. However, they did not help pa-
were equivalent. Although the mMRC grade tients who had milder exacerbations.
correlated well with overall health status, the Antibiotics may nevertheless have a role
cutoff mMRC grade of 2 or higher did not in ambulatory patients with mild to moderate
C L E V E L A N D C L I N I C J O U R N A L O F M E D I C I N E V O L U M E 8 1 N U M B E R 6 J U N E 2 0 1 4 375
Downloaded from www.ccjm.org on August 17, 2014. For personal use only. All other uses require permission.
COPD UPDATE
Downloaded from www.ccjm.org on August 17, 2014. For personal use only. All other uses require permission.
HATIPOGLU AND ABOUSSOUAN
Downloaded from www.ccjm.org on August 17, 2014. For personal use only. All other uses require permission.
HATIPOGLU AND ABOUSSOUAN
Downloaded from www.ccjm.org on August 17, 2014. For personal use only. All other uses require permission.
HATIPOGLU AND ABOUSSOUAN
C L E V E L A N D C L I N I C J O U R N A L O F M E D I C I N E V O L U M E 8 1 N U M B E R 6 J U N E 2 0 1 4 381
Downloaded from www.ccjm.org on August 17, 2014. For personal use only. All other uses require permission.
COPD UPDATE
382 C L E V E L A N D C L I N I C J O U R N A L O F M E D I C I N E V O L U M E 8 1 N U M B E R 6 J U N E 2 0 1 4
Downloaded from www.ccjm.org on August 17, 2014. For personal use only. All other uses require permission.
HATIPOGLU AND ABOUSSOUAN
57. Beeh KM, Beier J. The short, the long and the ultra-long: why duration
of bronchodilator action matters in chronic obstructive pulmonary disease.
Adv Ther 2010; 27:150159.
58. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebrovascu-
lar safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo
in COPD. Respir Med 2011; 105:571579.
59. Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, Rose-
braugh CJ. The risks and benefits of indacaterol--the FDAs review. N Engl J
Med 2011; 365:22472249.
60. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin
D on falls: a meta-analysis. JAMA 2004; 291:19992006.
61. Leech JA, Dulberg C, Kellie S, Pattee L, Gay J. Relationship of lung function
to severity of osteoporosis in women. Am Rev Respir Dis 1990; 141:6871.
62. Persson LJ, Aanerud M, Hiemstra PS, Hardie JA, Bakke PS, Eagan TM.
Chronic obstructive pulmonary disease is associated with low levels of
vitamin D. PLoS One 2012; 7:e38934.
63. Janssens W, Lehouck A, Carremans C, Bouillon R, Mathieu C, Decramer M.
Vitamin D beyond bones in chronic obstructive pulmonary disease: time to
act. Am J Respir Crit Care Med 2009; 179:630636.
64. Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to
reduce exacerbations in chronic obstructive pulmonary disease: a random-
ized trial. Ann Intern Med 2012; 156:105114.
65. Casanova C, Celli BR, Tost L, et al. Long-term controlled trial of nocturnal
nasal positive pressure ventilation in patients with severe COPD. Chest
2000; 118:15821590.
66. Dreher M, Storre JH, Schmoor C, Windisch W. High-intensity versus
low-intensity non-invasive ventilation in patients with stable hypercapnic
COPD: a randomised crossover trial. Thorax 2010; 65:303308.
67. McEvoy RD, Pierce RJ, Hillman D, et al; Australian trial of non-invasive
Ventilation in Chronic Airflow Limitation (AVCAL) Study Group. Nocturnal
non-invasive nasal ventilation in stable hypercapnic COPD: a randomised
controlled trial. Thorax 2009; 64:561566.
68. Dreher M, Ekkernkamp E, Walterspacher S, et al. Noninvasive ventilation
in COPD: impact of inspiratory pressure levels on sleep quality. Chest 2011;
140:939945.
69. Duiverman ML, Wempe JB, Bladder G, et al. Two-year home-based noctur-
nal noninvasive ventilation added to rehabilitation in chronic obstructive
pulmonary disease patients: a randomized controlled trial. Respir Res 2011;
12:112.
70. Ringbaek TJ, Broendum E, Hemmingsen L, et al. Rehabilitation of patients
with chronic obstructive pulmonary disease. Exercise twice a week is not
sufficient! Respir Med 2000; 94:150154.
71. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint
ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007;
131(suppl):4S42S.
72. Vallet G, Ahmadi S, Serres I, et al. Comparison of two training pro-
grammes in chronic airway limitation patients: standardized versus
individualized protocols. Eur Respir J 1997; 10:114122.
73. Vogiatzis I, Williamson AF, Miles J, Taylor IK. Physiological response to
moderate exercise workloads in a pulmonary rehabilitation program
in patients with varying degrees of airflow obstruction. Chest 1999;
116:12001207.
74. Martinez FJ, Vogel PD, Dupont DN, Stanopoulos I, Gray A, Beamis JF.
Supported arm exercise vs unsupported arm exercise in the rehabilitation
of patients with severe chronic airflow obstruction. Chest 1993; 103:1397
1402.
75. Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD.
Eur Respir J 2005; 26:630636.
76. Fishman A, Martinez F, Naunheim K, et al; National Emphysema Treatment
Trial Research Group. A randomized trial comparing lung-volume-reduc-
tion surgery with medical therapy for severe emphysema. N Engl J Med
2003; 348:20592073.
77. Naunheim KS, Wood DE, Mohsenifar Z, et al; National Emphysema Treat-
ment Trial Research Group. Long-term follow-up of patients receiving
lung-volume-reduction surgery versus medical therapy for severe emphy-
sema by the National Emphysema Treatment Trial Research Group. Ann
Thorac Surg 2006; 82:431443.
C L E V E L A N D C L I N I C J O U R N A L O F M E D I C I N E V O L U M E 8 1 N U M B E R 6 J U N E 2 0 1 4 383
Downloaded from www.ccjm.org on August 17, 2014. For personal use only. All other uses require permission.